These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1243 related articles for article (PubMed ID: 34937145)

  • 1. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
    Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
    N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
    Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
    Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    N Engl J Med; 2021 Mar; 384(10):905-914. PubMed ID: 33356051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
    Terzić V; Miantezila Basilua J; Billard N; de Gastines L; Belhadi D; Fougerou-Leurent C; Peiffer-Smadja N; Mercier N; Delmas C; Ferrane A; Dechanet A; Poissy J; Espérou H; Ader F; Hites M; Andrejak C; Greil R; Paiva JA; Staub T; Tacconelli E; Burdet C; Costagliola D; Mentré F; Yazdanpanah Y; Diallo A;
    Clin Infect Dis; 2024 Aug; 79(2):382-391. PubMed ID: 38552208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compassionate Use of Remdesivir for Patients with Severe Covid-19.
    Grein J; Ohmagari N; Shin D; Diaz G; Asperges E; Castagna A; Feldt T; Green G; Green ML; Lescure FX; Nicastri E; Oda R; Yo K; Quiros-Roldan E; Studemeister A; Redinski J; Ahmed S; Bernett J; Chelliah D; Chen D; Chihara S; Cohen SH; Cunningham J; D'Arminio Monforte A; Ismail S; Kato H; Lapadula G; L'Her E; Maeno T; Majumder S; Massari M; Mora-Rillo M; Mutoh Y; Nguyen D; Verweij E; Zoufaly A; Osinusi AO; DeZure A; Zhao Y; Zhong L; Chokkalingam A; Elboudwarej E; Telep L; Timbs L; Henne I; Sellers S; Cao H; Tan SK; Winterbourne L; Desai P; Mera R; Gaggar A; Myers RP; Brainard DM; Childs R; Flanigan T
    N Engl J Med; 2020 Jun; 382(24):2327-2336. PubMed ID: 32275812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
    Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
    J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
    Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
    PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    ITAC (INSIGHT 013) Study Group
    Lancet; 2022 Feb; 399(10324):530-540. PubMed ID: 35093205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
    Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
    N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.
    Chang HY; Hsu CC; Hu LF; Chou CY; Chang YL; Lu CC; Chang LJ
    Ann Med; 2024 Dec; 56(1):2361843. PubMed ID: 38830017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.